Treatment of AGRN-Related Congenital Myasthenic Syndrome
Ephedrine or its alternatives (pseudoephedrine, salbutamol) are the first-line treatment for AGRN-related congenital myasthenic syndrome, as these patients do not respond to standard anticholinesterase therapy used in other forms of myasthenia.
Primary Treatment Approach
AGRN-related CMS requires a fundamentally different therapeutic strategy than typical myasthenia gravis or other CMS subtypes. Anticholinesterase agents (pyridostigmine) should NOT be used as first-line therapy for AGRN mutations, as they are ineffective in this specific genetic subtype 1.
First-Line Medications
Ephedrine is the established treatment of choice:
- Both types of AGRN-related CMS respond favorably to ephedrine 1
- In the French National CMS Network experience, ephedrine was given to 18 patients including 4 with AGRN mutations, with good tolerability and encouraging therapeutic responses even in severely affected patients 1
- Dosing typically follows standard protocols used for other ephedrine-responsive CMS subtypes
Pseudoephedrine represents an effective alternative:
- A 2020 case report demonstrated remarkable curative effect with pseudoephedrine in an 8-year-old with AGRN compound heterozygous mutations 2
- This is the first documented report showing pseudoephedrine effectiveness for AGRN-related CMS 2
- Consider this option when ephedrine is unavailable or poorly tolerated
Salbutamol (albuterol) serves as another alternative:
- One patient showed marked response to salbutamol in a 2017 study 3
- Can be used when patients are allergic to ephedrine, as documented in the French cohort 1
- However, response may be variable—one patient in the 2020 report showed no improvement with salbutamol 2
Clinical Pitfalls and Monitoring
Common Diagnostic Confusion
AGRN-related CMS patients are frequently misdiagnosed initially:
- Often suspected of having spinal muscular atrophy (SMA), particularly when mutations affect agrin secretion 4
- In patients with clinical presentation of SMA but without SMN1 gene mutations, consider AGRN mutations 4
- May be confused with congenital myopathies due to muscle weakness, atrophy, and scoliosis 1
Key Clinical Features to Recognize
- Early age of onset (often infancy or birth) 2, 5
- Muscle weakness predominantly affecting lower limbs initially 2
- Both distal and proximal muscle involvement 3
- Fluctuation of symptoms with deterioration in afternoon or hot weather 3
- Repetitive nerve stimulation shows decremental response (typically 15-17% decrement at 3 Hz) 2, 3
Treatment Monitoring
- Assess motor function improvement, particularly proximal limb strength
- Monitor for reduction in fatigability
- Evaluate bulbar symptoms (dysphagia) if present
- Track respiratory function in severe cases
Disease Course Considerations
The long-term prognosis varies but AGRN patients generally have less severe disease progression compared to DOK7 mutations 1. Disease patterns can be variable throughout life in individual patients, with potential for:
- Progressive worsening
- Periods of exacerbation (pregnancy is a frequent trigger) 1
- Relative stability with treatment
Why Standard Myasthenia Treatments Fail
The pathophysiology of AGRN-related CMS differs fundamentally from acetylcholine receptor (AChR) deficiency syndromes. AGRN mutations cause:
- Impaired AChR clustering at the neuromuscular junction 3
- Protein instability and secretion defects 4
- Accumulation in endoplasmic reticulum with unfolded protein response 4
Since the problem is not acetylcholine availability or breakdown, cholinesterase inhibitors that increase acetylcholine concentration provide no benefit. Beta-adrenergic agonists (ephedrine, salbutamol) likely work through alternative mechanisms affecting neuromuscular junction function and muscle contractility.